Dr Karl Quint
Dr Karl Quint is a physician, scientist and the founder of Quint Healthcare. He works with medical technology, diagnostic and digital health organisations that need clinical judgement to inform product strategy, evidence, European regulation and implementation.
His professional perspective combines four environments that are often separated in healthcare projects: clinical medicine, translational research, regulated product development and business decision-making. This allows him to translate between clinicians, scientists, engineers, regulatory teams, management and investors without reducing the problem to any one of those viewpoints.
Clinical and scientific foundation
Karl studied medicine at Friedrich-Alexander-Universität Erlangen-Nürnberg and completed a doctoral dissertation on molecular and clinical features of pancreatic cancer with highest academic honours. His subsequent academic work included internal medicine, experimental hepatology and oncology, surgical research, neurology and pathology.
As a laboratory head and scientific project leader at Philipps-Universität Marburg, he helped rebuild a multidisciplinary translational research laboratory and digitise workflows across cell culture, histology, tissue analysis, digital pathology and molecular biology. At the University Hospital Erlangen, he worked as a resident physician and researcher in pathology, including histopathological diagnosis and gross pathology.
His research and clinical-study experience includes pancreatic and liver cancer, glioblastoma, molecular therapy, biomarkers, clinical investigations and translational surgical research. He has supervised medical doctoral theses, taught medical and scientific subjects and has served on the editorial board of Oncology Reports.
Medical technology and healthcare innovation
Dr. Karl Quint founded Quint Healthcare in 2014. Since then, his work has covered medical devices, in vitro diagnostics, digital health, software as a medical device, AI-enabled diagnostics, medical optics, sensors and clinical workflows.
Typical responsibilities include:
- defining clinical needs, intended purposes and medical requirements;
- planning clinical evidence and validation studies;
- preparing and reviewing clinical evaluations and post-market clinical follow-up;
- translating European regulatory requirements into product and evidence decisions;
- assessing German and European market-entry pathways;
- developing clinical user networks and adoption programmes;
- contributing medical leadership to multidisciplinary innovation projects;
- evaluating healthcare technologies, companies and grant proposals.
He completed a university certificate in medical product regulation covering clinical evaluation, risk management, usability, software, digital health and quality systems, as well as additional training in clinical studies under European medical-device law and ICH GCP.
International perspective
Quint Healthcare has worked with startups, scale-ups, established manufacturers, hospitals, universities, research institutes and investors in Europe, the United States and Israel. Karl has served as an expert evaluator for a European Commission executive agency since 2019 and as a mentor in European and international healthcare innovation networks.
The geographic boundary is explicit: regulatory work is centred on Germany and the European Union. Medical strategy, evidence planning, clinical concept development, due diligence and selected study work can support organisations internationally.
How he works
The starting point is usually a decision rather than a presentation: whether a claim is supportable, which evidence is necessary, which clinical workflow must change, whether a market-entry route is realistic, or where medical accountability belongs inside a project.
Karl's style is academically rigorous and commercially practical. Uncertainty is made visible, assumptions are tested early and deliverables are designed to help a team decide and act. Quint Healthcare works alongside regulatory consultancies, quality-management providers, CROs and specialist partners where their roles are required.
Related work
Karl is also a co-founder of Umami, an initiative focused on experiential learning, collaboration and leadership, and the founder and project lead of Humanitarian Aid Collaboration, which develops and delivers professional medical and civilian aid projects in crisis settings.
Discuss a project
For an initial conversation, bring the decision that is difficult to make and the evidence currently available. This makes it possible to establish quickly whether Quint Healthcare is the right partner and what a useful first scope would be.
